Gilead bets big on gene-editing platform

Feb 22, 2018

Kite, a Gilead Company, and Sangamo Therapeutics, have entered into a worldwide collaboration using Sangamo’s gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo.

Kite will use Richmond, California-based Sangamo’s zinc finger nuclease (ZFN) technology platform to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers.

Under the terms of the agreement, Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10 or more products utilizing Sangamo’s technology, based on the achievement of certain research, development, regulatory and successful commercialization milestones

Foster City, California-based Gilead bought Kite for $12 billion last year to get access to an emerging class of cancer immunotherapies called CAR-T. Gilead indicated earlier this year it would pursue collaborations with companies for gene-editing technology.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments